TriSalus Life Sciences (TLSI) directors re-elected and pay plan backed in 2026 vote

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

TriSalus Life Sciences, Inc. reported the results of its Annual Meeting of Stockholders. A total of 41,728,676 shares of common stock, representing 67.9% of outstanding shares, were present or represented, providing a solid quorum for the meeting’s business.

Stockholders elected Mary Szela and Gary Gordon as directors to serve three-year terms expiring at the 2029 annual meeting. The appointment of Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026 was also ratified by a wide margin.

On executive compensation matters, stockholders approved a three-year frequency for future advisory votes on named executive officer pay, and approved the current compensation of named executive officers on an advisory basis. Following the vote, the Board decided the company will hold say-on-pay votes every three years.

8-K Event Classification

Item 5.07 — Submission of Matters to a Vote of Security Holders

1 item

Item 5.07 Submission of Matters to a Vote of Security Holders Governance

Results of a shareholder vote on proposals at an annual or special meeting.

Key Figures

Shares represented: 41,728,676 shares Participation rate: 67.9% Director vote - Mary Szela: 31,393,310 for / 2,614,246 withhold +4 more

7 metrics

Shares represented 41,728,676 shares Common stock represented at the Annual Meeting

Participation rate 67.9% Percentage of total outstanding common shares represented

Director vote - Mary Szela 31,393,310 for / 2,614,246 withhold Election to three-year board term, plus 7,721,120 broker non-votes

Director vote - Gary Gordon 31,339,161 for / 2,668,395 withhold Election to three-year board term, plus 7,721,120 broker non-votes

Auditor ratification 41,098,385 for / 28,667 against Grant Thornton LLP for year ending December 31, 2026; 601,624 abstain

Say-on-pay frequency 20,348,386 votes for 3 years Stockholder advisory vote on frequency of executive pay votes

Say-on-pay approval 32,625,082 for / 1,206,105 against Advisory vote on named executive officer compensation; 176,369 abstain

Key Terms

broker non-votes, independent registered accounting firm, advisory basis, named executive officer compensation, +1 more

5 terms

broker non-votes financial

"Nominee | For | | Withhold | Broker Non-Votes Mary Szela | 31,393,310 | 2,614,246 | 7,721,120"

Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.

independent registered accounting firm financial

"The appointment of Grant Thornton, LLP to serve as our independent registered accounting firm for the fiscal year ending December 31, 2026"

advisory basis financial

"The proposal to approve, on an advisory basis, a three-year frequency with which the Company should conduct future stockholder advisory votes"

named executive officer compensation financial

"future stockholder advisory votes on named executive officer compensation was approved by the stockholder vote"

Pay and benefits disclosed for a company’s top executives identified in regulatory filings, including salary, bonuses, stock awards, option grants, pension contributions and other perks. Think of it as a public paycheck summary for senior managers that shows how they are rewarded and motivated. Investors use it to judge whether executive incentives align with shareholder interests, to assess potential costs and risks, and to evaluate corporate governance.

emerging growth company regulatory

"Emerging growth company o o On May 14, 2026, TriSalus Life Sciences, Inc."

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

Understanding 8-K Material Events →

05/14/2026 - 04:03 PM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 14, 2026

TRISALUS LIFE SCIENCES, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-39813	85-3009869
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)

6272 W 91st Ave, Westminster, Colorado		80031
(Address of principal executive office)		(Zip Code)

(888) 321-5212

(Registrant's telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions (see General Instruction A.2. below):
o			Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, $0.0001 par value	TLSI	Nasdaq Global Market
Warrants, each whole warrant exercisable for one share of registrant's common stock at an exercise price of $11.50 per share	TLSIW	Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


Item 5.07						Submission of Matters to a Vote of Security Holders.

On May 14, 2026, TriSalus Life Sciences, Inc. (the “Company”) held its Annual Meeting of Stockholders (the “Meeting”).

A total of 41,728,676 shares of our Common Stock, or 67.9% of the total outstanding shares, of our Common Stock were represented at the Meeting. The final voting results for each of the matters submitted to a stockholder vote at the Meeting are set forth below:

1.The two nominees for Directors were elected to serve three-year terms to expire at the annual meeting of stockholders in 2029, as follows:


Nominee	For	Withhold	Broker Non-Votes
Mary Szela	31,393,310	2,614,246	7,721,120
Gary Gordon	31,339,161	2,668,395	7,721,120

2.The appointment of Grant Thornton, LLP to serve as our independent registered accounting firm for the fiscal year ending December 31, 2026 was ratified by the stockholder vote:


For	Against	Abstain
41,098,385	28,667	601,624

3.The proposal to approve, on an advisory basis, a three-year frequency with which the Company should conduct future stockholder advisory votes on named executive officer compensation was approved by the stockholder vote:


1 Year	2 Years	3 Years	Abstain	Broker Non-Votes
12,656,430	736,931	20,348,386	265,809	7,721,120

After considering the results of the advisory vote, the Board of Directors approved a resolution that the Company will hold future stockholder advisory votes on named executive officer compensation every three years.

4.The proposal to approve, on an advisory basis, the compensation of the Company’s named executive officers was approved by the stockholder vote:


For	Against	Abstain	Broker Non-Votes
32,625,082	1,206,105	176,369	7,721,120

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Date: May 14, 2026	TriSalus Life Sciences, Inc.


	By:	/s/ David Patience
		Name:	David Patience
		Title:	Chief Financial Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did TriSalus Life Sciences (TLSI) stockholders vote on at the latest annual meeting?

Stockholders voted on director elections, ratification of the independent auditor, the preferred frequency of advisory votes on executive compensation, and an advisory say-on-pay resolution. All proposals received sufficient support to be approved based on the reported vote totals.

How many TriSalus Life Sciences (TLSI) shares were represented at the annual meeting?

A total of 41,728,676 shares of common stock were represented, equal to 67.9% of the total outstanding shares. This level of participation provided the quorum required to conduct official business and approve the proposals presented to stockholders.

Which directors were elected at the TriSalus Life Sciences (TLSI) annual meeting?

Stockholders elected Mary Szela and Gary Gordon as directors. Each will serve a three-year term scheduled to expire at the 2029 annual meeting of stockholders, based on the final vote counts reported in the meeting results.

Which audit firm did TriSalus Life Sciences (TLSI) stockholders ratify?

Stockholders ratified Grant Thornton LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026. The vote recorded 41,098,385 shares for, 28,667 against, and 601,624 abstentions, indicating strong support for the appointment.

How often will TriSalus Life Sciences (TLSI) hold advisory votes on executive compensation?

Stockholders supported a three-year frequency for advisory votes on named executive officer compensation, with 20,348,386 shares favoring that option. After reviewing the results, the Board resolved that future advisory say-on-pay votes will be held every three years.

Was executive compensation approved at the TriSalus Life Sciences (TLSI) annual meeting?

Yes. The advisory proposal on compensation for named executive officers received 32,625,082 votes for, 1,206,105 against, and 176,369 abstentions, plus 7,721,120 broker non-votes. This outcome indicates stockholder approval of the reported compensation program.

Filing Exhibits & Attachments

4 documents